Palynziq

Active Ingredient(s): Pegvaliase-pqpz
FDA Approved: * May 24, 2018
Pharm Company: * BIOMARIN PHARM
Category: Genetic Disorders

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Recent Palynziq Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pegvaliase-pqpz
  • Injection: 10mg/0.5ml, 2.5mg/o.5ml, 20mg/ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Palynziq: (3 results)

Sorted by National Drug Code
  • 68135-058 Palynziq 2.5 mg/.5ml Subcutaneous Injection, Solution by Biomarin Pharmaceutical Inc.
  • 68135-673 Palynziq 20 mg/ml Subcutaneous Injection, Solution by Biomarin Pharmaceutical Inc.
  • 68135-756 Palynziq 10 mg/.5ml Subcutaneous Injection, Solution by Biomarin Pharmaceutical Inc.

Other drugs which contain Pegvaliase-pqpz or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 25 September 2018.

We are committed to your privacy.

Copyright © 2005-2018 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 501 S. Cherry St, Suite 1100, Denver, CO, 80246, USA